CVRx, Inc. (CVRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CVRX Stock Price Chart Interactive Chart >
CVRX Price/Volume Stats
| Current price | $6.12 | 52-week high | $27.42 |
| Prev. close | $6.01 | 52-week low | $4.60 |
| Day low | $5.88 | Volume | 47,100 |
| Day high | $6.38 | Avg. volume | 128,194 |
| 50-day MA | $5.83 | Dividend yield | N/A |
| 200-day MA | $9.82 | Market Cap | 125.46M |
CVRx, Inc. (CVRX) Company Bio
CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.
Latest CVRX News From Around the Web
Below are the latest news stories about CVRx Inc that investors may wish to consider to help them evaluate CVRX as an investment opportunity.
2 ‘Strong Buy’ Stocks Insiders Are Snapping Up Right NowWhile the long-term outlook may predict a return to bullish conditions, for now investors have to contend with increased uncertainty and volatility. What they need is a sign, some signal to indicate stocks that are going to get through the current market environment. Insider trades are a common favorite among the signals available to investors, and for good reason. Corporate insiders – really, just company officers, positioned at the upper levels of management or the Boards, with an ‘inside’ view of everything behind the company and the stock – don’t trade lightly. |
CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating ResultsFourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year |
CVRx GAAP EPS of -$0.52 misses by $0.07, revenue of $3.7M misses by $0.07MCVRx press release (CVRX): Q4 GAAP EPS of -$0.52 misses by $0.07.Revenue of $3.7M (+76.2% Y/Y) misses by $0.07M. |
CVRx to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 15, 2022MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release fourth quarter and full year 2021 financial and operating results after market close on Tuesday, February 15, 2022. The Company will host a conference call to review its results at 5:30 p.m. Eastern Time the same |
CVRx sees Q4, FY 2021 and Q1 2022 revenue below consensusCVRx < |
CVRX Price Returns
| 1-mo | 0.99% |
| 3-mo | 0.00% |
| 6-mo | -49.88% |
| 1-year | -75.96% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -49.96% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...